

# Andrea Bacigalupo

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6305002/andrea-bacigalupo-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99  
papers

7,979  
citations

41  
h-index

89  
g-index

105  
ext. papers

9,311  
ext. citations

4.5  
avg, IF

5.58  
L-index

#	Paper	IF	Citations
99	Defining the intensity of conditioning regimens: working definitions. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 1628-33	4.7	1078
98	Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. <i>Blood</i> , <b>2003</b> , 102, 814-9	2.2	449
97	Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). <i>Blood</i> , <b>2001</b> , 98, 2942-7	2.2	413
96	Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. <i>Blood</i> , <b>2001</b> , 98, 972-8	2.2	304
95	Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2006</b> , 12, 560-5	4.7	287
94	Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 117-22	4.7	275
93	Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). <i>Haematologica</i> , <b>2007</b> , 92, 11-8	6.6	268
92	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , <b>2018</b> , 32, 1057-1069	10.7	263
91	Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1573-9	4.7	222
90	Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. <i>Lancet Oncology</i> , <b>2008</b> , 9, 831-9	21.7	216
89	Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. <i>Blood</i> , <b>2007</b> , 110, 1397-400	2.2	216
88	Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. <i>Seminars in Hematology</i> , <b>2000</b> , 37, 69-80	4	186
87	Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. <i>Blood</i> , <b>2005</b> , 105, 4115-9 <sup>2.2</sup>	2.2	176
86	How I treat acquired aplastic anemia. <i>Blood</i> , <b>2017</b> , 129, 1428-1436	2.2	169
85	Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. <i>Haematologica</i> , <b>2010</b> , 95, 976-82	6.6	163
84	Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 47-53	4.7	162
83	A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , <b>2011</b> , 117, 4434-41	2.2	150

82	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3627-3637	2.2	147
81	Treatment of acquired aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy[mdash ]The European Group for Blood and Marrow Transplantation Experience. <i>Seminars in Hematology</i> , <b>2000</b> , 37, 69-80	4	146
80	Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. <i>Blood</i> , <b>2006</b> , 107, 4177-81	2.2	140
79	Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. <i>Haematologica</i> , <b>2012</b> , 97, 1142-8	6.6	133
78	Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. <i>Blood</i> , <b>2012</b> , 119, 5391-6	2.2	126
77	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology,the</i> , <b>2020</b> , 7, e157-e167	14.6	116
76	Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 872-80	4.7	111
75	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. <i>Blood</i> , <b>2014</b> , 124, 1183-91	2.2	111
74	Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Haematologica</i> , <b>2008</b> , 93, 1514-22	6.6	109
73	Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. <i>British Journal of Haematology</i> , <b>2015</b> , 151, 505-91	4.5	108
72	Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. <i>Haematologica</i> , <b>2009</b> , 94, 1312-5	6.6	107
71	Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. <i>British Journal of Haematology</i> , <b>2001</b> , 112, 219-27	4.5	106
70	Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. <i>Haematologica</i> , <b>2015</b> , 100, 696-702	6.6	105
69	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 1525-1536	21.7	103
68	Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 331-8	21.7	93
67	Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , <b>2008</b> , 14, 993-1003	4.7	87
66	Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. <i>Haematologica</i> , <b>2017</b> , 102, 401-410	6.6	82
65	Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. <i>Haematologica</i> , <b>2006</b> , 91, 935-40	6.6	75

64	Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. <i>British Journal of Haematology</i> , <b>2009</b> , 144, 933-45	4.5	67
63	Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , <b>2004</b> , 89, 1238-47	6.6	57
62	Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. <i>British Journal of Haematology</i> , <b>2013</b> , 160, 503-9	4.5	52
61	Primary prophylaxis of invasive fungal diseases in allogeneic stem cell transplantation: revised recommendations from a consensus process by Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1080-8	4.7	47
60	Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2011</b> , 17, 901-7	4.7	46
59	CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 1440-3	4.7	43
58	Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 324-329	4.7	41
57	A Modified Post-Transplant Cyclophosphamide Regimen, for Unmanipulated Haploidentical Marrow Transplantation, in Acute Myeloid Leukemia: A Multicenter Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1243-1249	4.7	36
56	Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment. <i>Seminars in Hematology</i> , <b>2012</b> , 49, 15-24	4	35
55	Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2016</b> , 22, 1242-1246	4.7	34
54	Pre-Engraftment Bloodstream Infections after Allogeneic Hematopoietic Cell Transplantation: Impact of T Cell-Replete Transplantation from a Haploidentical Donor. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 109-118	4.7	31
53	The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. <i>Blood Advances</i> , <b>2017</b> , 1, 669-680	7.8	30
52	Bone marrow transplantation versus immunosuppressive therapy in patients with acquired severe aplastic anemia. <i>International Journal of Hematology</i> , <b>2016</b> , 104, 168-74	2.3	29
51	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. <i>Oncotarget</i> , <b>2016</b> , 7, 43027-43038	3.3	29
50	Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved?. <i>Blood</i> , <b>2018</b> , 131, 1989-1992	2.2	27
49	Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 119-126	4.7	25
48	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1223-1233	2.2	25
47	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , <b>2020</b> , 105, 47-58	6.6	25

46	Combining flow cytometry and assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia. <i>Haematologica</i> , <b>2017</b> , 102, e348-e351	6.6	22
45	Haemopoietic stem cell transplants: the impact of haemorrhagic complications. <i>Blood Reviews</i> , <b>2003</b> , 17 Suppl 1, S6-10	11.1	22
44	Alternative donor transplants for severe aplastic anemia: current experience. <i>Seminars in Hematology</i> , <b>2016</b> , 53, 115-9	4	19
43	Haploidentical hematopoietic stem cell transplantation in aplastic anemia: a systematic review and meta-analysis of clinical outcome on behalf of the severe aplastic anemia working party of the European group for blood and marrow transplantation (SAAWP of EBMT). <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1906-1917	4.4	17
42	Alternative donor transplants for severe aplastic anemia. <i>Hematology American Society of Hematology Education Program</i> , <b>2018</b> , 2018, 467-473	3.1	16
41	Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 1987-1994	4.4	15
40	First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 643-648	7.1	15
39	Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation. <i>Haematologica</i> , <b>2020</b> , 105, 1223-1231	6.6	14
38	Haploidentical donor transplants for severe aplastic anemia. <i>Seminars in Hematology</i> , <b>2019</b> , 56, 190-193	4	14
37	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1915-1922	4.7	14
36	Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 932-940	4.7	14
35	Steroid treatment of acute graft-host disease grade I: a randomized trial. <i>Haematologica</i> , <b>2017</b> , 102, 2125-2133	6.6	13
34	Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. <i>Blood Advances</i> , <b>2020</b> , 4, 3900-3912	7.8	12
33	Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 708-712	4.4	10
32	Bone marrow or peripheral blood as a source of stem cells for allogeneic transplantation. <i>Haematologica</i> , <b>2002</b> , 87, 4-8	6.6	10
31	Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody-Begelomab. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1580-1587	4.4	9
30	Bone marrow haploidentical transplant with post-transplantation cyclophosphamide: does graft cell content have an impact on main clinical outcomes?. <i>Cytotherapy</i> , <b>2020</b> , 22, 158-165	4.8	8
29	Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 698-703	4.7	7

28	Use of Bone Marrow or Peripheral Blood Stem Cell Grafts in Non T Cell Depleted Haploidentical Transplants Using Post-Transplant Cyclophosphamide, an ALWP-EBMT Analysis. <i>Blood</i> , <b>2016</b> , 128, 1165-1165	2.2	6
27	Unrelated cord blood transplantation and post-transplant cyclophosphamide. <i>Haematologica</i> , <b>2019</b> , 104, e77-e78	6.6	6
26	Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia of the Elderly: Review of Literature and New Perspectives. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2020</b> , 12, e2020081	3.2	4
25	Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 234-240	7.1	4
24	Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 1560-1567	4.4	4
23	Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study. <i>International Journal of Hematology</i> , <b>2021</b> , 114, 228-234	2.3	3
22	Second haploidentical stem cell transplantation for primary graft failure. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1291-1296	4.4	3
21	2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 1532-1538	7.1	3
20	Antithymocyte globulin in the conditioning regimen: why not?. <i>Biology of Blood and Marrow Transplantation</i> , <b>2014</b> , 20, 597-8	4.7	2
19	Bone marrow transplantation for acquired aplastic anemia: What's new. <i>Best Practice and Research in Clinical Haematology</i> , <b>2021</b> , 34, 101284	4.2	2
18	Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome. <i>Journal of Clinical Immunology</i> , <b>2018</b> , 38, 7-9	5.7	1
17	Identifying the Best Haploidentical Donor: Are We There?. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 638-640	4.7	1
16	High Predictive Value of Pre Transplant Minimal Residual Disease Assessment By Combining WT1 Expression and Flow Cytometry in Acute Myeloid Leukemia. <i>Blood</i> , <b>2015</b> , 126, 2029-2029	2.2	1
15	Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)?. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2021</b> , 13, e2021062	3.2	1
14	Reducing infectious complications after allogeneic stem cell transplant. <i>Expert Review of Hematology</i> , <b>2020</b> , 13, 1235-1251	2.8	1
13	Failure to effectively treat chronic graft-versus-host disease: a strong call for prevention. <i>Haematologica</i> , <b>2016</b> , 101, e214-5	6.6	1
12	Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , <b>2021</b> , 107, 573-582	3.8	1
11	Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 637512	8.4	0

- 10 ABO Mismatch in Allogeneic Hematopoietic Stem Cell Transplant: Effect on Short- and Long-term Outcomes. *Transplantation Direct*, **2021**, 7, e724 2.3 0
- 9 Myeloablative Versus Nonmyeloablative Conditioning Regimen in Haploidentical Transplantation: Does It Matter and How Best to Select Between the Two? **2018**, 159-171
- 8 High vs low dose cyclosporine-a, after allogeneic marrow transplantation in leukemia: Long term follow up of a randomized study. *American Journal of Hematology*, **2018**, 93, E185 7.1
- 7 Trajectory of lung function to pleuroparenchymal fibroelastosis late after haematopoietic stem-cell transplantation. *Respiratory Medicine Case Reports*, **2019**, 28, 100915 1.2
- 6 Established Drugs and Emerging Targets in Aplastic Anemia **2021**,
- 5 Haploidentical HSCT **2019**, 479-486
- 4 Unrelated Cord Blood Transplantation and Post-Transplant Cyclophosphamide (PT-CY). *Blood*, **2019**, 134, 3332-3332 2.2
- 3 A 30-month-old boy with aplastic anemia caused by electrocution. *Annals of Hematology*, **2020**, 99, 2439-2440
- 2 Skin chronic GVHD **2021**, 140-165
- 1 Hemorrhagic cystitis in allogeneic stem cell transplantation: a role for age and prostatic hyperplasia.. *Supportive Care in Cancer*, **2022**, 1 3.9